WITHUS PHARMACEUTICALLTD Balance Sheet Health
Financial Health criteria checks 5/6
WITHUS PHARMACEUTICALLTD has a total shareholder equity of ₩92.6B and total debt of ₩19.8B, which brings its debt-to-equity ratio to 21.4%. Its total assets and total liabilities are ₩130.9B and ₩38.3B respectively. WITHUS PHARMACEUTICALLTD's EBIT is ₩8.3B making its interest coverage ratio 33.1. It has cash and short-term investments of ₩11.8B.
Key information
21.4%
Debt to equity ratio
₩19.77b
Debt
| Interest coverage ratio | 33.1x |
| Cash | ₩11.84b |
| Equity | ₩92.59b |
| Total liabilities | ₩38.31b |
| Total assets | ₩130.90b |
Recent financial health updates
Recent updates
These 4 Measures Indicate That WITHUS PHARMACEUTICALLTD (KOSDAQ:330350) Is Using Debt Reasonably Well
Nov 13
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Financial Position Analysis
Short Term Liabilities: A330350's short term assets (₩57.1B) exceed its short term liabilities (₩31.1B).
Long Term Liabilities: A330350's short term assets (₩57.1B) exceed its long term liabilities (₩7.2B).
Debt to Equity History and Analysis
Debt Level: A330350's net debt to equity ratio (8.6%) is considered satisfactory.
Reducing Debt: A330350's debt to equity ratio has reduced from 23.6% to 21.4% over the past 5 years.
Debt Coverage: A330350's debt is not well covered by operating cash flow (19.2%).
Interest Coverage: A330350's interest payments on its debt are well covered by EBIT (33.1x coverage).